Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

BACKGROUND Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...

Chong-Rui Xu, Yan Zhang, G. Lin et al. · 1 citation
Case report Open access Aug 2026

Combination of PD-1 inhibitor and chemotherapy for subcutaneous soft-tissue metastasis in postoperative non-small cell lung cancer

This case suggests that combining chemotherapy with programmed cell death protein 1 inhibition may provide rapid and effective tumor control in advanced non-small cell lung cancer patients with bulky, symptomatic metastases, while maintaining a manageable safety profile.

Qiang Zeng, Bin Yang, Yang Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.